A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation (LIBREXIA-AF)
J
John Strobel, MD
Primary Investigator
Enrolling By Invitation
18 years and older
All
Phase
3
15500 participants needed
1 Location
Overview
The purpose of this study is to evaluate if milvexian is at least as effective as apixabanducing the risk of the composite stroke and non- central nervous system (CNS) systemicbolism.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Atrial Fibrillation
-
Age: 18 Years
-
Gender: All
Inclusion Criteria:
- Minimum age of 18 years
- Medically stable and appropriate for chronic antithrombotic treatment
- Atrial fibrillation eligible to receive anticoagulation
- Participant must satisfy one or both of the following categories of risk factors (a orb): a) one or more of the following risk factors: i) age greater than or equal to 75years, ii) history of a clinical symptomatic stroke. b) two or more of the followingk factors: i) age between 65 and 74 years, ii) hypertension, iii) diabetesus, iv) atherosclerotic vascular disease, v) heart failure
Exclusion Criteria:
- Hemodynamically significant valve disease or those with valve disease that willy require surgical valve replacement during the study
- Any condition other than AF that requires chronic anticoagulation
Updated on
15 May 2024.
Study ID: CR109220
Please visit our main page to search for other studies you may be interested in.
If you need help finding a study or have any questions, please contact us at inhealth@iu.edu
